New pill targets Hard-to-Treat cancers with specific gene mutation
Disease control
Recruiting now
This early-phase study tests a new oral drug, DO-2, in adults with advanced solid tumors (like lung cancer) that have a specific MET gene change and no standard treatment options left. The main goal is to check the drug's safety and find the right dose. About 55 participants will…
Phase: PHASE1 • Sponsor: DeuterOncology • Aim: Disease control
Last updated May 04, 2026 16:17 UTC